The aim of this study was to clarify the prevalence and prognostic role of c-MET expression in prostate cancer by using a pre-existing tissue microarray (TMA) including more than 4,000 prostate cancers, the majority with clinical follow-up data. The gene discussed is MET; the disease is prostate carcinoma.